Objective-Bone marrow-derived mononuclear cells (BMCs) improve the functional recovery after ischemia. However, BMCs comprise a heterogeneous mixture of cells, and it is not known which cell types are responsible for the induction of neovascularization after cell therapy. Because cell recruitment is critically dependent on the expression of the SDF-1-receptor CXCR4, we examined whether the expression of CXCR4 may identify a therapeutically active population of BMCs. Methods and Results-Human CXCR4 ϩ and CXCR4 Ϫ BMCs were sorted by magnetic beads. CXCR4 ϩ BMCs showed a significantly higher invasion capacity under basal conditions and after SDF-1 stimulation. Hematopoietic or mesenchymal colony-forming capacity did not differ between CXCR4 ϩ and CXCR4 Ϫ BMCs. Injection of CXCR4 ϩ BMCs in mice after induction of hindlimb ischemia significantly improved the recovery of perfusion compared to injection of CXCR4 Ϫ BMCs. Likewise, capillary density was significantly increased in CXCR4 ϩ BMC-treated mice. Because part of the beneficial effects of cell therapy were attributed to the release of paracrine effectors, we analyzed BMC supernatants for secreted factors. Importantly, supernatants of CXCR4 ϩ BMCs were enriched in the proangiogenic cytokines HGF and PDGF-BB. Conclusion-CXCR4 ϩ BMCs exhibit an increased therapeutic potential for blood flow recovery after acute ischemia.
D espite improved interventional and pharmacological therapy, postinfarction heart failure remains a challenge in patients with large myocardial infarctions. 1, 2 Cell therapy may provide a novel therapeutic option to modify left ventricular remodeling processes and prevent postinfarction heart failure. Several clinical pilot trials and randomized studies showed beneficial effects of cell therapy on left ventricular ejection fraction. 3 In addition, intracoronary administration of bone marrow-derived mononuclear cells (BMCs) was shown to be associated with a significant reduction of the occurrence of major adverse cardiovascular events after AMI. 4 Most of the clinical studies used BMCs isolated from bone marrow aspirates by density gradient centrifugation for intracoronary cell therapy (for review see 5, 6 ). BMCs comprise a heterogeneous mixture of cells containing endothelial progenitor cells (EPCs), hematopoietic progenitor cells, mesenchymal stem cells (MSCs), multipotent adult mesenchymal progenitors, and very small embryonic-like (VSEL) stem cells. Although various studies provide evidence that selected endothelial/hematopoietic progenitor cells expressing the marker CD34 or CD133, 7, 8 cultured MSCs, 9 -11 and VSEL cells 12 improve the recovery after acute myocardial infarction, the subsets of cells responsible for these beneficial effects of total BMCs are not yet identified.
The chemokine stromal cell-derived factor-1 (SDF-1) and its specific receptor, CXCR4, play a pivotal role in normal cardiovascular development as well as postnatal neovascularization. [13] [14] [15] [16] [17] The cytokine SDF-1 is released in response to hypoxia and acts as a chemo-attracting factor to recruit CXCR4-expressing cells to sites of ischemia. 13 CXCR4 is expressed by hematopoietic and endothelial progenitor cells, but also by stromal cells, endothelial cells, and lymphocytes. 18 -21 The expression of the CXCR4 receptor is important for cell migration, hematopoietic progenitor cell engraftment to the bone marrow, and the recruitment of endothelial and hematopoietic progenitor cells, as well as proangiogenic cells to improve neovascularization in mouse models of ischemia. 17, 18, [22] [23] [24] [25] [26] [27] Recently, it was shown that CXCR4 upregulation by hypoxia enhances the benefit of cell therapy. 28 Because CXCR4 expression plays a crucial role in cell engraftment, we investigated whether the expression of CXCR4 may identify a population of BMCs with a higher capacity to improve the recovery after ischemia. The results of the present study demonstrate that CXCR4 ϩ BMCs exhibit significantly higher invasion capacity under basal conditions and in response to SDF-1, whereas the capacity of CXCR4 ϩ and CXCR4 Ϫ to generate hematopoietic or mesenchymal colony-forming units was similar. Injection of CXCR4 ϩ BMCs was significantly more effective in improving neovascularization in a hindlimb ischemia model. Consistently, CXCR4 ϩ cells released higher levels of proangiogenic cytokines.
Materials and Methods

Isolation of Bone Marrow Mononuclear Cells
Bone marrow aspirates were obtained from healthy volunteers without any evidence of CAD by history and physical examination (supplemental Table I ). The Ethics Review Board of the Hospital of the Johann Wolfgang Goethe University of Frankfurt, Germany approved the protocol, and the study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each volunteer. BMCs were isolated as described previously. 29 Briefly, bone marrow aspirates were diluted with 0.9% NaCl (1:5), were filtrated (100 m) and mononuclear cells were isolated by density gradient centrifugation using Ficoll (Cambrex; 800g, 20 minutes, without brake). Mononuclear cells were washed 3 times with 50 mL PBS (800g), were counted, and used for the experiments.
Antibodies, Sorting, and FACS Analysis
CXCR4-antibody (clone 1D9; BD) as well as the neutralizing CXCR4-antibody (clone 12G5; R&D) were used for the experiments. CXCR4 ϩ BMCs were isolated using immunomagnetic CXCR4-microbeads (Miltenyi Biotec, Germany) and a magnetic cell separation device (Midi-MACS; Miltenyi Biotec). Briefly, BMC suspensions were incubated for 30 minutes with PE-conjugated anti-CXCR4 antibody, extensively washed, and then incubated for 1 hour with anti-Phycoerythrin (PE) MicroBeads. After washing, cells were separated on LD(ϩ) columns for positive and negative selection, respectively, according to the manufacturer's instructions. CXCR4-expression of sorted fractions was checked by FACS-analysis with the PE-conjugated sorting antibody (Becton Dickinson, FACS Canto II).
In addition, total BMCs as well as sorted fractions were stained with antibodies against CD4, CD8, CD11b, CD14, CD34, CD38, CD45 (all Becton Dickinson), CD133 (Miltenyi Biotec), and KDR (R&D) and analyzed by FACS.
Colony-Forming Unit Assay
BMCs (1ϫ10 5 per dish) were seeded in methylcellulose plates (Methocult GF H4534; StemCell). Plates were studied under phasecontrast microscopy, and colony-forming units (CFU; colonies Ͼ50 cells) were counted after 14 days of incubation at 37°C. CFUs were examined in duplicate.
Assessment of Invasion Capacity of BMCs
A total of 1ϫ10 6 BMCs were resuspended in 250 L x-vivo 15 medium and placed in the upper chamber of a modified Boyden chamber filled with Matrigel (BioCoat invasion assay, 8-m pore size, Becton Dickinson). Then, the chamber was placed in a 24-well culture dish containing 500 L x-vivo 15 medium. For some experiments, 100 ng/mL stromal cell-derived factor 1 (SDF-1) was added to the lower chamber. After 24 hours of incubation at 37°C, transmigrated cells were counted. Invasion assays were run in duplicates.
Assessment of Mesenchymal Stem Cells Colonies
A total of 1ϫ10 6 BMCs were resuspended in 3.5 mL MesenCult (StemCell), plated on a T 25 culture flask, and cultured at 37°C. Medium was changed every second day. After 2 weeks, adherent cells were fixed with a mixture of methanol/acetic acid (4:1) for 30 minutes, washed, and stained with 1% crystal violet. Colonies were counted macroscopically. All assays were run in triplicate.
Hindlimb Ischemia Model
The neovascularization capacity of BMCs was investigated in a murine model of hindlimb ischemia by use of 8-to 10-week-old athymic NMRI nude mice (Charles River, Sulzfeld, Germany) weighing 18 to 22 g. The femoral artery including the superficial and the deep branches as well as the distal portion of the saphenous artery were chronically ligated with an electric coagulator. The overlying skin was closed with 3 surgical staples. After 24 hours, 1ϫ10 6 BMCs/mouse were injected intravenously.
Limb Perfusion Measurements
Two weeks after induction of hindlimb ischemia, blood flow ratio of the ischemic to normal limb was measured by using a laser Doppler blood flowmeter (Laser Doppler Perfusion Imager System, moorLDI-Mark 2). The perfusion of the ischemic and nonischemic limb was calculated on the basis of colored histogram pixels. To minimize variables including ambient light and temperature and to maintain a constant body temperature, mice were exposed to infrared light for 10 minutes before laser Doppler scans. The calculated perfusion was expressed was the ratio of ischemic to nonischemic hindlimb perfusion.
Histological Evaluation
Capillary density was determined in 5-m frozen sections of the adductor and semimembranous muscles from the ischemic and the nonischemic limbs. Endothelial cells were stained with a FITClabeled monoclonal antibody directed against CD31 (Chemicon), myocytes with Laminin (Abcam). The area of the whole muscle was counted, and capillary density was expressed as number of capillaries per myocyte.
Cytokine Arrays
Cytokine arrays were performed according to the manufacturer's protocol (RayBiotech Inc). Briefly, membranes were blocked and supernatants of 5ϫ10 6 BMCs were incubated at 4°C overnight. After incubation with biotinylated-anticytokin and streptavidin-HRP and several washing steps, the signals were detected using ECL-Hyperfilm (Amersham) and semiquantitative analysis was performed using the Tina-software 2.09 (Raytest).
Statistical Analysis
If not stated otherwise, data are shown as meanϮSEM. Statistical comparisons were made by the 2-sided t test or the nonparametric Mann-Whitney U test. Statistical significance was assumed at a value of PϽ0.05.
Results
Establishment of CXCR4 ؉ Cell Isolation
The functional activity of the CXCR4 receptor is essential for migration and in vivo engraftment. To exclude that the antibody used to sort CXCR4 ϩ cells interferes with CXCR4 receptor activity, we tested the effect of 2 different CXCR4 antibodies on SDF-1-induced invasion in vitro. As shown in Figure 1 , the clone 12G5 blocked CXCR4 activity and significantly reduced SDF-1-induced invasion capacity of BMCs, whereas the clone 1D9 did not alter BMC invasion capacity ( Figure 1 ). Therefore, the CXCR4 antibody clone 1D9 was used for the further sorting experiments.
For that purpose, BMCs isolated by Ficoll density gradient centrifugation were incubated with the PE-conjugated CXCR4 antibody and were isolated with anti-PE-conjugated magnetic beads. After sorting, cell fractions were examined by FACS analysis. The CXCR4 ϩ fraction was enriched to 68%, and only a minor contamination of CXCR4 ϩ cells was detected in the CXCR4 Ϫ fraction (Ͻ5%; see Figure 2 ).
To assess the functional activity of the sorted cells, we determined the invasion capacity of CXCR4 ϩ and CXCR4 Ϫ BMCs under basal conditions and in response to SDF-1. CXCR4 ϩ BMCs showed a significantly higher invasion under basal conditions compared to CXCR4 Ϫ BMCs. Moreover, as expected, CXCR4 Ϫ BMCs were nonresponsive to the chemoattractant SDF-1 (Figure 3 ).
CXCR4 ؉ BMCs Improve Neovascularization After Ischemia
To address whether sorted CXCR4 ϩ cells exhibit a higher capacity to therapeutically improve neovascularization, the same number of CXCR4 ϩ and CXCR4 Ϫ cells were injected into nude mice after induction of hindlimb ischemia. Two weeks after induction of ischemia, CXCR4 ϩ cell-treated mice showed a moderate but significantly greater recovery of limb perfusion measured by laser Doppler-derived blood flow compared to mice treated with CXCR4 Ϫ cells or PBS ( Figure  4A , supplemental Figure I ). Consistently, histological assessment of the skeletal muscles revealed that treatment with CXCR4 ϩ cells significantly increased the number of CD31 ϩ capillaries compared to the CXCR4 Ϫ cell-treated group (Figure 4B and 4C) . However, the enhancement of neovascularization achieved by total unsorted BMCs was higher compared to isolated CXCR4 ϩ cells at day 21 after ischemia (supplemental Figure I) .
Characterization of Cells Enriched in the Isolated CXCR4 ؉ Cells
The improved therapeutic benefit of CXCR4 ϩ cells might be attributable to an enrichment of a specific subpopulation of cells. Therefore, we characterized the composition of CXCR4 ϩ and CXCR4 Ϫ cells by FACS. However, the number of previously identified proangiogenic cells such as hematopoietic progenitor cells (defined as CD34 ϩ or CD133 ϩ cells) or cells expressing the endothelial marker KDR (VEGF-receptor 2) with or without coexpression of CD34, was not different in CXCR4 ϩ and CXCR4 Ϫ subpopulations ( Figure 5A and 5B) . Consistent with these data, the number of granulocyte-monocyte colony-forming units, as a functional readout of hematopoietic progenitor cells, was similar in CXCR4 ϩ and CXCR4 Ϫ cells ( Figure 5C ). Likewise, the number of MSCs did not differ ( Figure 5D ) indicating that the improved benefit of CXCR4 ϩ cells is unlikely caused by an enrichment of previously identified endothelial, hematopoietic, or mesenchymal progenitor cells.
Because immune cells were shown to affect arteriogenesis and angiogenesis, we additionally characterized the presence of myeloid and lymphoid subpopulations. Interestingly, CD14 ϩ monocytic cells and CD38 ϩ lymphocytes as well as CD4 ϩ and CD45 ϩ cells were significantly enriched in the purified CXCR4 ϩ fraction, whereas CD8 ϩ cells were not different between CXCR4 ϩ and CXCR4 Ϫ BMCs (Figure 5E and 5F).
Cytokine Secretion Differs Between CXCR4 ؉ and CXCR4 ؊ BMCs
Increasing evidence suggests that paracrine factors released by the transplanted cells contribute to the functional recovery after ischemia. 30 -33 Therefore, we determined the release of cytokines into the supernatants of CXCR4 ϩ and CXCR4 Ϫ cells by using cytokine arrays. Consistent with previous studies using EPCs or BMCs, 30, 34 CXCR4 ϩ cells released high levels of proangiogenic growth factors including SDF-1, VEGF, HGF-1, IGF-1 angiopoietin-1, and PDGF. There was no difference in levels of the majority of the cytokines released into the supernatants of CXCR4 ϩ and CXCR4 Ϫ cells. Of note, CXCR4 ϩ cells showed a significantly higher release of HGF and PDGF-BB compared to CXCR4 Ϫ cells ( Figure 6 ). Moreover, a strong trend toward a higher release was detected with respect to the antiinflammatory cytokine IL-10 ( Figure 6 ). In order to address the relevance of CXCR4 ϩ cell-mediated release of human HGF and PDGF-BB, we used antibodies neutralizing these cytokines. The combination of these neutralizing antibodies reduced the enhancement of laser Doppler-derived blood flow mediated by CXCR4 ϩ cells (supplemental Figure II) .
Discussion
The data of the present study demonstrate that selection of CXCR4 ϩ from total bone marrow mononuclear cells enriches a cell population with a higher invasion activity in vitro and an improved capacity to therapeutically augment neovascularization after ischemia in an animal model in vivo.
The improved therapeutic benefit of CXCR4 ϩ cells may be rationalized by the capacity of these cells to respond to the hypoxia-regulated chemokine SDF-1 and by the increased basal invasive capacity of the cells. Especially, if cells are applied by an intravascular route of administration, the response of cells to chemokines is a prerequisite for recruitment, homing, and subsequent engraftment of transplanted cells into the target area. Previous studies have demonstrated that the functional activity of progenitor cells-measured ex vivo as SDF-1-induced migratory capacity-correlates with the neovascularization improvement of the infused cells in a hindlimb ischemia model of nude mice. 35 Moreover, in a clinical pilot trial of intracoronary cell therapy, the migratory capacity of EPCs and BMCs toward a gradient of VEGF or SDF-1 predicted the reduction of infarct size in patients treated with the respective progenitor cells after myocardial infarction. 36 In addition, Tang et al recently showed that upregulation of CXCR4 in progenitor cells by hypoxia profoundly increases their invasion capacity in vitro as well as the recovery after cell therapy in acute myocardial infarction by increasing the recruitment of the cells to the ischemic tissue. 28 The importance of the SDF-1/CXCR4 axis is additionally supported by experimental studies showing that bone marrow-derived mononuclear cells isolated from heterozygous CXCR4 mice, which exhibit an approximately 50% reduction of CXCR4 receptor surface expression, entirely failed to augment neovascularization after infusion in a hindlimb ischemia model. 18 Moreover, storage-induced reduced CXCR4-expression was associated with a significant reduc- tion of cell migration as well as a reduced capacity of BMCs to improve the recovery after hindlimb ischemia. 29 Although it has to be acknowledged that CXCR4 surface expression is rapidly changing by endocytosis and recycling of the receptor, 37, 38 we could demonstrate that CXCR4 surface expression remains significantly higher expressed in CXCR4 ϩ BMC up to 24 hours under in vitro conditions (data not shown). Thus, the lack of benefit of the CXCR4 Ϫ cells might be explained by the lack of response to recruitment and homing signals.
Interestingly, CXCR4 ϩ cells additionally were characterized by a different release pattern of cytokines, which might act in a paracrine manner to support neovascularization and repair. One of the two identified significantly upregulated cytokines is HGF, which is well known to play an important role in endothelial and myocardial regeneration. 39 Previous studies documented that HGF contributes to cardiac regeneration by affecting tissue resident progenitor cells, inhibiting apoptosis, and improving angiogenesis. 40, 41 Moreover, transplanted adipose tissue-derived cells were shown to promote angiogenesis by their secretion of HGF. [42] [43] [44] Clinical studies additionally demonstrated that elevated HGF levels are associated with improved coronary collateralization in patients with acute coronary syndromes. 45, 46 The second cytokine, which was significantly elevated in the supernatant of CXCR4 ϩ cells, is the proangiogenic growth factor PDGF-BB. PDGF-BB increases endothelial cell proliferation and migration 47 and promotes angiogenesis in vitro. 48 Moreover, PDGF-BB was therapeutically applied to promote collateral development after arterial occlusion, 49 and the release of PDGF-BB is thought to contribute to the functional benefit of transplanted multipotent adult progenitor cells. 50 Given the important biological activities of these cytokines and the finding that neutralizing antibodies directed against human HGF and PDGF-BB reduce the therapeutic benefit of CXCR4 ϩ BMCs, it is likely that CXCR4 ϩ BMCs might promote neovascularization at least in part by secreting HGF and PDGF-BB.
An interesting aspect of the present study also relates to the finding that the population of isolated CXCR4 ϩ cells does not contain higher numbers of the previously described proangiogenic endothelial and hematopoietic cell population. However, it appears that selection of CXCR4 ϩ cells results in an enrichment of CD14 ϩ monocytes and CD38 ϩ lymphoid cells. Although the functional relevance of the enrichment in CD14 ϩ and CD38 ϩ cells has not been determined, one may speculate that the enriched cells may have contributed to the differential cytokine profile of the cell supernatants or may have effects in the target tissue. Whereas the endogenous contribution of myeloid and lymphoid cells to angiogenesis and arteriogenesis has been established, 51, 52 it is unclear to what extent selected immune cells might be useful for cell therapy to increase endogenous repair mechanisms or to modulate inflammatory responses after tissue injury. The demonstration that MSCs or unselected BMCs exhibit immune-regulatory functions (eg, by releasing IL-10 in a model of acute myocardial infarction 31 ) indicates that cell therapy may indeed interfere with the immune response after injury. 53 Recently, while this study was under revision, a clinical trial addressed whether sorted CD34 ϩ CXCR4 ϩ BMCs exhibit superior effects compared to total BMCs in patients with acute myocardial infarction. However, the individual responses of the patients receiving CXCR4 ϩ CD34 ϩ cells were very heterogeneous, as indicated by the large standard deviations of the recovery of left ventricular function as measured by ejection fraction. Moreover, the extent of increase in ejection fraction was similar in the CXCR4 ϩ CD34 ϩ -cell treated group compared to the unselected BMC-treated group. 54 At least, these data indicate that sorting of CXCR4 ϩ cells does not provide a therapeutic advantage, and the results are consistent with our finding showing a moderate effect of sorted CXCR4 ϩ cells, which was not superior to total BMCs. Further studies have to elucidate to what extent the antibodies and beads used for sorting might have been affecting cell functionality.
In summary, our data demonstrate that CXCR4 ϩ BMCs represent a subpopulation within the bone marrow capable of improving neovascularization after acute ischemia, whereas CXCR4 Ϫ cells lack any therapeutic benefit. Figure 6 . Cytokine secretion of CXCR4 ϩ and CXCR4 Ϫ BMCs. Supernatants of 5ϫ10 6 CXCR4 Ϫ /CXCR4 ϩ BMCs were examined for cytokines by precoated membranes (cytokine array, RayBiotech Inc) In the upper part representative membranes are shown, and the lower part shows the quantification of nϭ4 cytokine arrays using supernatants of BMCs from 4 different healthy donors; data are meanϮSEM, *PϽ0.05 vs CXCR4 Ϫ BMCs.
